Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

TLG2289-4-cover

For many patients with non–small-cell lung cancer (NSCLC), immunotherapy is now becoming the standard of care. Immunotherapy given as monotherapy or in combination with other agents has contributed to promising results in NSCLC, with the earliest results observed in 2015 with nivolumab, and subsequently leading to FDA approval of 6 agents.

Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

Marianne Davies, DNP, ACNP, AOCNP, FAAN Associate Professor, Yale School of Nursing Yale University West Haven, CT Oncology Nurse Practitioner-Thoracic & Solid Tumor Senior Advanced Practice Provider II Smilow Cancer Hospital at Yale-New Haven Yale Comprehensive Cancer Center New Haven, CT Shawn Perkins, RN, BSN, OCN Thoracic Nurse Navigator UNC [ Read More ]